Intervention
HRS-6209
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 2 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
2 shownA Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer PatientsNCT06679036 · 2025-01-21
RECRUITINGFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyNCT05582499 · 2022-11-01
RECRUITINGCommon conditions
Advanced Unresectable or Metastatic Breast Cancer1Breast Cancer1Breast Neoplasm1Breast Tumors1Early-stage Breast Cancer1HER2-negative Breast Cancer1HER2-positive Breast Cancer1Hormone Receptor Negative Tumor1Hormone Receptor Positive Tumor1Locally Advanced Breast Cancer1Triple-Negative Breast Cancer (TNBC)1
Leading sponsors
Trial status mix
RECRUITING2
Phase mix
PHASE22
PHASE11
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.